ArticlePharmaceutical research2000
Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides.
Article in Pharmaceutical research, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Defining Endocytic Pathways of Fucoidan-Coated PIBCA Nanoparticles from the Design of their Surface Architecture.Pharmaceutical research · 2022Article
- Development and immunobiological evaluation of nanoparticles containing an immunodominant epitope of herpes simplex virus.IET nanobiotechnology · 2021Article
- Anti-Inflammatory Activity of Bullfrog Oil Polymeric Nanocapsules: From the Design to Preclinical Trials.International journal of nanomedicine · 2021Article
- Radical Polymerization of Alkyl 2-Cyanoacrylates.Molecules (Basel, Switzerland) · 2018Review
- Nanocapsules: the weapons for novel drug delivery systems.BioImpacts : BI · 2012Article
- Preparation and characterization of magnetic nanoparticles containing Fe(3)O(4)-dextran-anti-β-human chorionic gonadotropin, a new generation choriocarcinoma-specific gene vector.International journal of nanomedicine · 2011Article
- Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.Clinical and vaccine immunology : CVI · 2010Article
- Nanocarriers' entry into the cell: relevance to drug delivery.Cellular and molecular life sciences : CMLS · 2009Review
- Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.British journal of pharmacology · 2009Review
- Methods for the preparation and manufacture of polymeric nanoparticles.Pharmaceutical research · 2009Review
- Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma.Pharmaceutical research · 2006Article
- Polymeric particulates to improve oral bioavailability of peptide drugs.Molecules (Basel, Switzerland) · 2005Review
- Oligonucleotides targeted against a junction oncogene are made efficient by nanotechnologies.Pharmaceutical research · 2003Article
- Top-down particle fabrication: control of size and shape for diagnostic imaging and drug delivery.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe goal of the present paper was to encapsulate oligonucleotides in a new particulate carrier in order to protect them from enzymatic degradation.
methodsNanocapsules with an aqueous core containing oligonucleotides were prepared by interfacial polymerization of isobutylcyanoacrylate in a W/O emulsion. Ultracentrifugation and re-suspension in water yielded a dispersion of these containing an aqueous core nanocapsules. Zeta potential measurements and quenching of fluorescence of fluorescein-bounded oligonucleotides were used to study the localization of the oligonucleotides. Oligonucleotide degradation studies were carried out in fetal calf serum.
resultsPolydisperse nanocapsules of size ranging from 20 to 400 nm were obtained. Oligonucleotide loading did not significantly influence the zeta potential, suggesting they were located within the core of the nanocapsules. Fluorescence quenching assays confirmed this localization. When encapsulated in the nanocapsules and incubated in the presence of serum, the oligonucleotides were efficiently protected from degradation by nucleases, whereas oligonucleotides adsorbed onto nanospheres were protected less efficiently.
conclusionsThis paper describes, for the first time, a nanotechnology able to encapsulate oligonucleotides rather than adsorbing them at the surface of a solid support. Such a formulation has great potential for oligonucleotide delivery.
Indexed as
Identifiers
10955845What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.